Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion
- PMID: 18541823
- PMCID: PMC2748247
- DOI: 10.1001/archinte.168.11.1159
Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion
Abstract
Background: Resistant hypertension is a common clinical problem and greatly increases the risk of target organ damage.
Methods: We evaluated the characteristics of 279 consecutive patients with resistant hypertension (uncontrolled despite the use of 3 antihypertensive agents) and 53 control subjects (with normotension or hypertension controlled by using <or=2 antihypertensive medications). Participants were prospectively examined for plasma aldosterone concentration, plasma renin activity, aldosterone to renin ratio, brain-type natriuretic peptide, atrial natriuretic peptide, and 24-hour urinary aldosterone (UAldo), cortisol, sodium, and potassium values while adhering to a routine diet.
Results: Plasma aldosterone (P < .001), aldosterone to renin ratio (P < .001), 24-hour UAldo (P = .02), brain-type natriuretic peptide (P = .007), and atrial natriuretic peptide (P = .001) values were higher and plasma renin activity (P = .02) and serum potassium (P < .001) values were lower in patients with resistant hypertension vs controls. Of patients with resistant hypertension, men had significantly higher plasma aldosterone (P = .003), aldosterone to renin ratio (P = .02), 24-hour UAldo (P < .001), and urinary cortisol (P < .001) values than women. In univariate linear regression analysis, body mass index (P = .01), serum potassium (P < .001), urinary cortisol (P < .001), urinary sodium (P = .02), and urinary potassium (P < .001) values were correlated with 24-hour UAldo levels. Serum potassium (P = .001), urinary potassium (P < .001), and urinary sodium (P = .03) levels were predictors of 24-hour UAldo levels in multivariate modeling.
Conclusions: Aldosterone levels are higher and there is evidence of intravascular volume expansion (higher brain-type and atrial natriuretic peptide levels) in patients with resistant hypertension vs controls. These differences are most pronounced in men. A significant correlation between 24-hour urinary aldosterone levels and cortisol excretion suggests that a common stimulus, such as corticotropin, may underlie the aldosterone excess in patients with resistant hypertension.
Figures


Similar articles
-
The effect of adrenal surgery on plasma atrial natriuretic factor and sodium escape phenomenon in patients with primary aldosteronism.J Urol. 1989 Jul;142(1):13-8. doi: 10.1016/s0022-5347(17)38650-0. J Urol. 1989. PMID: 2525199
-
Hemodynamic, hormone, and urinary effects of adrenomedullin infusion in essential hypertension.Hypertension. 2000 Oct;36(4):588-93. doi: 10.1161/01.hyp.36.4.588. Hypertension. 2000. PMID: 11040240 Clinical Trial.
-
Refractory ascites in cirrhosis: roles of volume expansion and plasma atrial natriuretic factor level elevation.Hepatology. 1993 Sep;18(3):519-28. Hepatology. 1993. PMID: 8395457
-
Atrial natriuretic peptide: a new factor in hormonal control of blood pressure and electrolyte homeostasis.Annu Rev Med. 1986;37:397-414. doi: 10.1146/annurev.me.37.020186.002145. Annu Rev Med. 1986. PMID: 2939792 Review.
-
Type II pseudohypoaldosteronism. Report of a case and review of the literature.J Endocrinol Invest. 1994 Jun;17(6):453-7. doi: 10.1007/BF03347738. J Endocrinol Invest. 1994. PMID: 7930391 Review.
Cited by
-
[Resistant hypertension : What is it?].Internist (Berl). 2015 Mar;56(3):224-9. doi: 10.1007/s00108-014-3568-9. Internist (Berl). 2015. PMID: 25668441 German.
-
Relationship of resistant hypertension and treatment outcomes with total arterial compliance in a predominantly African American hypertensive cohort.J Clin Hypertens (Greenwich). 2012 Sep;14(9):618-22. doi: 10.1111/j.1751-7176.2012.00653.x. Epub 2012 May 18. J Clin Hypertens (Greenwich). 2012. PMID: 22947360 Free PMC article.
-
Brazilian Position Statement on Resistant Hypertension - 2020.Arq Bras Cardiol. 2020 May-Jun;114(3):576-596. doi: 10.36660/abc.20200198. Arq Bras Cardiol. 2020. PMID: 32267335 Free PMC article. English, Portuguese. No abstract available.
-
Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure.Can J Cardiol. 2016 May;32(5):603-6. doi: 10.1016/j.cjca.2015.06.033. Epub 2015 Jul 8. Can J Cardiol. 2016. PMID: 26514749 Free PMC article.
-
Renin angiotensin aldosterone system altered in resistant hypertension in Sub-Saharan African diabetes patients without evidence of primary hyperaldosteronism.JRSM Cardiovasc Dis. 2017 Feb 1;6:2048004017695006. doi: 10.1177/2048004017695006. eCollection 2017 Jan-Dec. JRSM Cardiovasc Dis. 2017. PMID: 28321294 Free PMC article.
References
-
- Gifford RW, Tarzi RC. Resistant hypertension: diagnosis and management. Ann Intern Med. 1978;88:661–5. - PubMed
-
- Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–52. - PubMed
-
- Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199–206. - PubMed
-
- Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) J Clin Hypertens (Greenwich) 2002;4:393–404. - PubMed
-
- Black HR, Eliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073–82. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical